Panbela Therapeutics (NASDAQ:PBLA) Stock Price Up 7.3%

Panbela Therapeutics, Inc. (NASDAQ:PBLA)’s stock price was up 7.3% during mid-day trading on Thursday . The company traded as high as $0.48 and last traded at $0.44. Approximately 25,779 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 573,537 shares. The stock had previously closed at $0.41.

Analyst Ratings Changes

Separately, Roth Mkm restated a “buy” rating on shares of Panbela Therapeutics in a research report on Wednesday, March 27th.

Panbela Therapeutics Stock Performance

The stock has a market cap of $1.53 million, a PE ratio of 0.00 and a beta of 1.48. The company has a 50 day moving average of $0.75 and a two-hundred day moving average of $8.06.

Panbela Therapeutics (NASDAQ:PBLA) last released its earnings results on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing the consensus estimate of ($24.34) by ($41.56). As a group, equities research analysts anticipate that Panbela Therapeutics, Inc. will post -5.25 EPS for the current year.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.